share_log

Nova Mentis to Enter MRNA AI Diagnostics Business

Nova Mentis to Enter MRNA AI Diagnostics Business

Nova Mentis 將進入 MRNA 人工智能診斷業務
newsfile ·  2023/04/26 20:32

Vancouver, British Columbia--(Newsfile Corp. - April 26, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the launch of SwabAi Diagnostics Inc. (SwabAi).

溫哥華,不列顛哥倫比亞省-(Newsfile Corp.-2023年4月26日)-Nova Mentis生命科學公司(CSE:NOVA)(FSE:HN3Q)(OTCQB:NMLSF)(“Nova”或“公司”),一家生物技術公司和一流的以裸蓋菇素為基礎的治療神經炎性疾病的治療和補充診斷的全球領先企業高興地宣佈推出SwabAi診斷公司(SwabAi)。

On June 16, 2022, NOVA filed a patent titled "Diagnosing, Monitoring and Treating Neurological Disease With Psychoactive Tryptamine Derivatives and mRna Measurements."

2022年6月16日,Nova公司申請了一項名為精神活性色胺衍生物及其mRNA檢測在神經系統疾病診斷、監測和治療中的應用

The Company intends to unleash the full potential of this technology as a stand-alone business. NOVA's wholly owned subsidiary, Pilz Bioscience Inc., will undergo a name change to SwabAi Diagnostics, Inc. prior to a planned corporate spinout.

該公司打算將這項技術作為一項獨立的業務來充分釋放潛力。Nova的全資子公司Pilz Bioscience Inc.將在計劃剝離公司之前更名為SwabAi Diagnostics,Inc.。

"NOVA's novel mRNA technology has the potential to assess the neuroinflammatory condition of a patient on initial evaluation and ability to monitor drug treatment response. This genomic technology opens the door for the development of breakthrough products in psychedelic medicine. We believe this technology can be used by the pharmaceutical industry to evaluate efficacy of drugs in the treatment of chronic inflammatory disorders of the central nervous system," stated Will Rascan, NOVA's President & CEO.

諾華公司首席執行官總裁兼首席執行官威爾·拉斯坎說:“諾華公司的新型信使核糖核酸技術有可能在初步評估時評估患者的神經炎症狀況,並有能力監測藥物治療反應。這項基因組技術為開發致幻藥物的突破性產品打開了大門。我們相信,製藥行業可以利用這項技術來評估藥物在治療中樞神經系統慢性炎症性疾病方面的療效。”

Using buccal swab samples that are easily collected from patients, SwabAi has developed a proprietary diagnostic panel that examines a 52-mRNA microarray output using machine learning AI to uncover inflammatory gene patterns associated with specific neuroinflammatory conditions.

使用從患者身上輕鬆收集的口腔拭子樣本,SwabAi開發了一個專有的診斷小組,該小組使用機器學習人工智慧檢查52-mRNA微陣列輸出,以揭示與特定神經炎性疾病相關的炎症基因模式。

Currently, in the evaluation and treatment of various neurological and psychological diseases, efficacy measurements are largely dependent on patient and professional observer feedback through standardized and accepted questionnaires that have a biased component. NOVA's goal in utilizing its mRNA biomarker panel technology is to assess the physiological changes that may be occurring in a patient throughout the course of treatment. This information will provide practitioners with an additional layer of objective data points from which to base drug dosages as well as response to treatment.

目前,在各種神經和心理疾病的評估和治療中,療效測量在很大程度上依賴於患者和專業觀察員通過標準化和可接受的具有偏見的調查問卷的反饋。Nova利用其信使核糖核酸生物標記物面板技術的目標是評估患者在整個治療過程中可能發生的生理變化。這些資訊將為從業者提供額外的一層客觀數據點,以作為藥物劑量和治療反應的基礎。

"This technology has far-reaching implications and merits over and above its utilization in our current Health Canada approved Phase IIA fragile X syndrome clinical studies," said Derek Ivany, NOVA's Executive Chairman. "SwabAi plans to assess potential synergistic corporate development opportunities with companies in the neuroscience arena."

Nova執行主席德里克·伊萬尼說:“這項技術在我們目前加拿大衛生部批准的IIA期脆性X綜合徵臨床研究中具有深遠的影響和優點。SwabAi計劃評估與神經科學領域公司潛在的協同企業發展機會。“

According to Statista, in 2021, artificial intelligence (AI) in the healthcare market was worth around US$11 billion worldwide. It was forecast that the global healthcare AI market could be worth almost US$188 billion by 2030, increasing at a compound annual growth rate of 37 percent from 2022 to 2030.

根據Statista的數據,2021年,醫療保健市場中的人工智慧(AI)在全球的價值約為110億美元。據預測,到2030年,全球醫療保健人工智慧市場的價值可能達到近1880億美元,從2022年到2030年,復合年增長率為37%。

NOVA believes that its proprietary mRNA diagnostic technology is not realizing its full value nor commercialization potential within the current corporate framework. As such, management and the Board of Directors are considering distributing its ownership of the standalone entity, SwabAi, to NOVA shareholders. Further details such as finalization, timing and the exchange ratio will be determined in due course. Although management believes that this proposal has commercial as well as shareholder value, there is no assurance at this time that the spinout will be enacted.

Nova認為,其專有的信使核糖核酸診斷技術在目前的公司框架內沒有充分發揮其價值或商業化潛力。因此,管理層和董事會正在考慮將其對獨立實體SwabAi的所有權分配給Nova股東。進一步的細節,如敲定、時間和交換比例將在適當時候確定。儘管管理層認為這項提議既有商業價值,也有股東價值,但目前還不能保證剝離會得到實施。

About Nova Mentis Life Science Corp.

關於Nova Mentis生命科學公司

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova Mentis生命科學公司是一家總部位於加拿大的生物技術公司,在開發神經炎性疾病的診斷和基於裸蓋菇素的療法方面處於全球領先地位。Nova是第一家在美國和歐盟獲得使用裸蓋菇素治療脆性X綜合徵(FXS)的孤兒藥物指定的生物技術公司。

NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

Nova的目標是診斷和治療尚未滿足醫療需求的令人衰弱的慢性疾病,如自閉症譜系障礙(ASD)和FXS。

For further information on the Company, please visit or email info@novamentis.ca.

欲瞭解更多有關公司的資訊,請訪問或發送電子郵件至info@novamentis.ca。

On Behalf of the Board

我謹代表董事會

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

威爾·拉斯坎,總裁兼首席執行官
Nova Mentis生命科學公司

Phone: 778-819-0244
Toll Free: 1-833-542-5323

電話:778-819-0244
免費電話:1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

推特:@novamentislsc
Instagram:@novamentislsc
臉書:@novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新聞稿包含構成“前瞻性陳述”的陳述。此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素,可能導致Nova Mentis生命科學公司的實際結果、業績或成就或行業發展與此類前瞻性表述明示或暗示的預期結果、業績或成就大不相同。前瞻性陳述是指不是歷史事實的陳述,通常但並非總是由“預期”、“計劃”、“預期”、“相信”、“打算”、“估計”、“專案”、“潛在”和類似的表述,或事件或條件“將”、“將”、“可能”、“可能”或“應該”發生。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論